Business
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity –– PRGN-3005 cells demonstrated expansion
About this update from Precigen, Inc.
[{"type":"text","content":"– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity –– PRGN-3005 cells demonstrated expansion and persistence when delivered via either intraperitoneal or intravenous infusion without lymphodepletion or via intravenous infusion after lymphodepletion demonstrating the effectiveness of mbIL15 –– A single intravenous infusion following lymphodepletion decreased tumor burden in 67% of the heavily pretreated patients (median of 8 or more prior therapies) with 90% of individual target lesions showing stable disease or partial response –– PRGN-3005 UltraCAR-T cells are being evaluated in the Phase 1b dose expansion study with intravenous infusion following lymphodepletion and incorporating repeat infusion –– Best responder achieved stable disease for more than 18 months after failing 9 prior lines of treatment; results achieved with two doses of UltraCAR-T cells in the low millions –\nGERMANTOWN, Md., June 5, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from the Phase 1 portion of the Phase 1/1b clinical study evaluating safety and efficacy of PRGN-3005 UltraCAR-T® in advanced stage platinum resistant ovarian cancer patients (Abstract# 5590). The presentation was delivered by John B. Liao, MD, PhD, Cancer Vaccine Institute, University of Washington Medicine, and a lead investigator for the PRGN-3005 clinical trial.\n\"We are pleased with the results of the Phase 1 study which demonstrate a favorable safety profile for PRGN-3005 UltraCAR-T. Our UltraCAR-T therapies continue to be well-tolerated with no dose limiting toxicities across our clinical stage UltraCAR-T portfolio,\" said Helen Sabzevari, PhD, President and CEO of Precigen. \"At this early stage, we are encouraged that patients in the IV plus lymphodepletion arm showed stable or partial response in 90% of the individual target lesions, and that the case study presented demonstrated that the repeat dosing further decreased tumor burden. UltraCAR-T is the only CAR-T platform that has demonstrated the ability to expand and persist and show a reduction in tumor burden and lesions wit...